PWS
TGTX icon

Precision Wealth Strategies’s TG Therapeutics TGTX Stock Holding History

Precision Wealth Strategies’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,488
Closed -$523K – 184
2025
Q3 		$523K Buy
+14,488
New +$477K 0.17% 126
2025
Q1 		– Sell
-17,608
Closed -$530K – 120
2024
Q4 		$530K Buy
+17,608
New +$505K 0.41% 43

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Precision Wealth Strategies's TGTX Position: Q4 2025 in Review

Precision Wealth Strategies sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 14,488 shares — an estimated $523K sold.

Precision Wealth Strategies first reported a position in TGTX in Q4 2024 and held it in 2 quarters. The position peaked at $530K in Q4 2024. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Precision Wealth Strategies reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Precision Wealth Strategies sold 14,488 TG Therapeutics shares in Q4 2025, an estimated $523K.
  • Precision Wealth Strategies first reported a position in TG Therapeutics in Q4 2024 and held it in 2 quarters.
  • Precision Wealth Strategies's TG Therapeutics position peaked at $530K in Q4 2024.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Precision Wealth Strategies's 13F filing for Q4 2025, filed 30 Jan 2026.